Evidence map›Paper›PMID 38408353›Full record

ArticleThe Journal of infectious diseases2024

A Novel Ex Vivo Assay to Evaluate Functional Effectiveness of Plasmodium vivax Transmission-Blocking Vaccine Using Pvs25 Transgenic Plasmodium berghei.

Yi Cao, Clifford T H Hayashi, Nirbhay Kumar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yi CaoDepartment of Global Health, Milken Institute School of Public Health, George Washington University, Washington, District of Columbia, USA.ORCID 0000-0001-8780-1350
Clifford T H HayashiDepartment of Global Health, Milken Institute School of Public Health, George Washington University, Washington, District of Columbia, USA.
Nirbhay KumarDepartment of Global Health, Milken Institute School of Public Health, George Washington University, Washington, District of Columbia, USA.ORCID 0000-0002-0358-4924

Funding

Combination Vaccines to Interrupt Malaria TransmissionR01AI127544 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KUMAR, NIRBHAY · 2017 to 2020
$2.2M
George Washington UniversityNIAID NIH HHS R01 AI127544NIH HHS R01
6 · The paper itself

Abstract

backgroundPlasmodium falciparum and Plasmodium vivax account for >90% global malaria burden. Transmission intervention strategies encompassing transmission-blocking vaccines (TBV) and drugs represent ideal public health tools to eliminate malaria at the population level. The availability of mature P. falciparum gametocytes through in vitro culture has facilitated development of a standard membrane feeding assay to assess efficacy of transmission interventions against P. falciparum. The lack of in vitro culture for P. vivax has significantly hampered similar progress on P. vivax and limited studies have been possible using blood from infected patients in endemic areas. The ethical and logistical limitations of on-time access to blood from patients have impeded the development of P. vivax TBVs.

methodsTransgenic murine malaria parasites (Plasmodium berghei) expressing TBV candidates offer a promising alternative for evaluation of P. vivax TBVs through in vivo studies in mice, and ex vivo membrane feeding assay (MFA).

resultsWe describe the development of transmission-competent transgenic TgPbvs25 parasites and optimization of parameters to establish an ex vivo MFA to evaluate P. vivax TBV based on Pvs25 antigen.

conclusionsThe MFA is expected to expedite Pvs25-based TBV development without dependence on blood from P. vivax-infected patients in endemic areas for evaluation.

Indexed as

Malaria VaccinesMalaria, VivaxPlasmodium bergheiPlasmodium vivaxAnimalsAntigens, ProtozoanAntigens, SurfaceFemaleHumansMiceAntigens, ProtozoanAntigens, SurfaceMalaria VaccinesPvs25 protein, P vivaxmembrane feeding assayPlasmodium vivaxPvs25transgenic P. bergheitransmission-blocking vaccine

Identifiers

PMID38408353
PMCPMC11175679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.